About Immunic, Inc.
https://www.immunic-therapeutics.comImmunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases.
CEO
Daniel Vitt
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-04-15 | Reverse | 1:40 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ABRDN PLC
Shares:8.24M
Value:$5.36M
BVF INC/IL
Shares:7.65M
Value:$4.97M
AVIDITY PARTNERS MANAGEMENT LP
Shares:4.7M
Value:$3.05M
Summary
Showing Top 3 of 72
About Immunic, Inc.
https://www.immunic-therapeutics.comImmunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $25.99M ▼ | $-25.58M ▲ | 0% | $-0.13 ▲ | $-25.58M ▲ |
| Q2-2025 | $0 | $27.08M ▲ | $-26.82M ▼ | 0% | $-0.2 ▲ | $-27.04M ▼ |
| Q1-2025 | $0 | $26.82M ▲ | $-25.47M ▼ | 0% | $-0.25 ▲ | $-26.78M ▼ |
| Q4-2024 | $0 | $25.6M ▼ | $-25.18M ▼ | 0% | $-0.28 ▼ | $-25.14M ▲ |
| Q3-2024 | $0 | $25.73M | $-24.37M | 0% | $-0.24 | $-25.68M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $35.13M ▼ | $40.7M ▼ | $30.2M ▲ | $10.5M ▼ |
| Q2-2025 | $55.31M ▲ | $61.43M ▲ | $27.52M ▲ | $33.91M ▲ |
| Q1-2025 | $14.3M ▼ | $20.52M ▼ | $25.8M ▲ | $-5.29M ▼ |
| Q4-2024 | $35.67M ▼ | $40.87M ▼ | $22.44M ▼ | $18.43M ▼ |
| Q3-2024 | $59.07M | $64.76M | $23.54M | $41.22M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-25.58M ▲ | $-20.14M ▲ | $-67K ▼ | $0 ▼ | $-20.18M ▼ | $-20.21M ▲ |
| Q2-2025 | $-26.82M ▼ | $-24.61M ▼ | $-36K ▲ | $65.52M ▲ | $41.01M ▲ | $-24.64M ▼ |
| Q1-2025 | $-25.47M ▼ | $-21.78M ▲ | $-47K ▼ | $0 ▼ | $-21.36M ▲ | $-21.82M ▲ |
| Q4-2024 | $-25.18M ▼ | $-22.96M ▼ | $-3K ▲ | $77K ▲ | $-23.4M ▼ | $-22.97M ▼ |
| Q3-2024 | $-24.37M | $-20.8M | $-50K | $0 | $-20.63M | $-20.85M |
CEO
Daniel Vitt
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-04-15 | Reverse | 1:40 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ABRDN PLC
Shares:8.24M
Value:$5.36M
BVF INC/IL
Shares:7.65M
Value:$4.97M
AVIDITY PARTNERS MANAGEMENT LP
Shares:4.7M
Value:$3.05M
Summary
Showing Top 3 of 72